BNTCBenitec Biopharma Inc.
- Earnings Call Transcripts
Lonza AG - 1773841 - Lonza AG
So hello everyone and thank you for joining this session of the Morgan Stanley Global Healthcare Conference. I am Thibault Boutrin. I'm part of the European Pharma Equity Research Team based in London. Before we start th ...
- Analyst Upgrades
Wedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $17
Wedbush analyst Yun Zhong maintains Benitec Biopharma with a Outperform and raises the price target from $16 to $17. ...
- Analyst Upgrades
This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top Wall Street analysts changed outlook on top names. See all rating changes on analyst ratings page. Analysts have positive views on FTH stock. ...
- Analyst Upgrades
Wedbush Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $16
Wedbush analyst Yun Zhong initiates coverage on Benitec Biopharma with a Outperform rating and announces Price Target of $16. ...
- GlobeNewswire
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 24-months ...
- Analyst Upgrades
Evercore ISI Group Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $25
Evercore ISI Group analyst Cory Kasimov initiates coverage on Benitec Biopharma with a Outperform rating and announces Price Target of $25. ...
- GlobeNewswire
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
- Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 completers, 24-month post-treatment follow-up results for the first Cohort 1 ...
- BusinessWire
PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that ...
- BusinessWire
Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
Dr. Mates grew Intra-Cellular from discovery and early innovation through commercialization of CAPLYTA® and a $14.6 billion acquisition by Johnson & Johnson Seaport Therapeutics ("Seaport" or the "Company"), ...
- GlobeNewswire
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)
HAYWARD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based ...
- Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Benitec Biopharma, Maintains $32 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Benitec Biopharma with a Buy and maintains $32 price target. ...
- GlobeNewswire
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
- Oculopharyngeal Muscular Dystrophy (OPMD) Patients treated with low dose BB-301 and high dose BB-301 experienced significant improvements in throat closure, throat emptying, and total dysphagic symptom burden - OPMD ...
- GlobeNewswire
Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference
-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first Cohort 1 Patient, and ...
- GlobeNewswire
Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update
-The first 4 Patients enrolled into Cohort 1 of the BB-301 Phase 1b/2a treatment study have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at the 12-month ...
- GlobeNewswire
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with deepening improvements ...
- Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Benitec Biopharma, Lowers Price Target to $32
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Benitec Biopharma with a Buy and lowers the price target from $35 to $32. ...
- GlobeNewswire
Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update
–Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for ...
- GlobeNewswire
Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering
HAYWARD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines ...
- GlobeNewswire
Benitec Biopharma Inc. Announces Proposed Public Offering
HAYWARD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines ...
- Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Benitec Biopharma, Raises Price Target to $35
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Benitec Biopharma with a Buy and raises the price target from $28 to $35. ...
- Analyst Upgrades
Citizens Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $22
Citizens analyst Silvan Tuerkcan maintains Benitec Biopharma with a Market Outperform and raises the price target from $20 to $22. ...
- GlobeNewswire
Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301
Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301 BB-301 has also been granted ...
- GlobeNewswire
Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors
HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based ...
- GlobeNewswire
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy
HAYWARD, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines ...
- SEC
DEFA14A Form - Additional definitive proxy soliciting materials and Rule 14(a)(12) material - Benitec Biopharma Inc. (0001808898) (Filer)
Additional definitive proxy soliciting materials and Rule 14(a)(12) material ...